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Unfavourable gender effect of 
high body mass index on brain 
metabolism and connectivity
Maura Malpetti1, Arianna Sala1,2, Emilia Giovanna Vanoli3, Luigi Gianolli3, Livio Luzi4 & 
Daniela Perani1,2,3
The influence of Body Mass Index (BMI) on neurodegeneration in dementia has yet to be elucidated. 
We aimed at exploring the effects of BMI levels on cerebral resting-state metabolism and brain 
connectivity, as crucial measures of synaptic function and activity, in a large group of patients with 
Alzheimer’s Dementia (AD) (n = 206), considering gender. We tested the correlation between BMI levels 
and brain metabolism, as assessed by 18F-FDG-PET, and the modulation of the resting-state functional 
networks by BMI. At comparable dementia severity, females with high BMI can withstand a lower 
degree of brain metabolism dysfunction, as shown by a significant BMI-brain metabolism correlation 
in the temporal-parietal regions, which are typically vulnerable to AD pathology (R = 0.269, p = 0.009). 
Of note, high BMI was also associated with reduced connectivity in frontal and limbic brain networks, 
again only in AD females (p < 0.05 FDR-corrected, k = 100 voxels). This suggests a major vulnerability 
of neural systems known to be selectively involved in brain compensatory mechanisms in AD females. 
These findings indicate a strong gender effect of high BMI and obesity in AD, namely reducing the 
available reserve mechanisms in female patients. This brings to considerations for medical practice and 
health policy.
The interaction between Body Mass Index (BMI) and cognition in healthy status, and the role of BMI as a risk 
factor for dementia are complex and highly debated issues1–3. There is growing evidence that obesity (BMI > 
30 kg/m2) is linked to reduced cognitive functions in adults, particularly in executive, attention, and memory 
domains3–5. Epidemiological evidence on the risk of developing dementia in obesity is controversial. The complex 
interplay between BMI and the risk of developing cognitive decline might be modulated by age. Some stud-
ies reported a significant association between high BMI and cognitive deficits in young subjects6, and also a 
higher risk of developing dementia in midlife7,8. Despite the results in young adults and middle-aged subjects 
consistently suggest a negative effect of high BMI on cognitive functions, the evidence in late life is less clear. 
Epidemiological findings in elderly suggest a protective effect of high BMI against dementia (see for reviews1–3). 
This evidence merges in the “obesity paradox” hypothesis9, which again suggests a positive correlation between 
BMI levels and dementia risk in mid-life (age up to 60–65 years), but a protective effect of high BMI in late life 
(age 65–70 years or older) instead. To explain this discrepancy in late life, it has been suggested that low BMI may 
be a consequence of the loss of weight preceding the onset of dementia in older people10,11. An accelerated reduc-
tion in BMI during late life has been also reported to precede the clinical detection of dementia, while a slower 
decline in BMI has been associated with a reduced dementia risk1. Therefore, it is possible that low or declining 
BMI is a factor associated with the development of dementia rather than a risk factor. On the other hand, a life-
long high BMI has been equally suggested as a risk factor for cognitive decline and dementia by several studies, 
which reported an increased risk of developing cognitive decline in overweight or obese individuals across the 
lifespans3,6,12.
In spite of the extensive epidemiological data, neuroimaging studies are scarce and the neural mechanisms 
underlying the effect of BMI in dementia remain currently unknown. 18F-fluorodeoxyglucose Positron Emission 
Tomography (18F-FDG-PET) is a well-recognized tool to study brain dysfunction in dementia13,14. 18F-FDG-PET 
measures of resting-state brain metabolism, which is a direct in vivo index of synaptic function13, were applied in 
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studies on modifiable risk and protective factors for dementia, although not on BMI. For example, there is large 
evidence for low education and occupation levels, low physical and leisure activities as risk factors for all demen-
tia conditions15,16. On the other hand, life experiences such as high education17–19, occupation17,18 and bilingual-
ism20 are known to be involved in the modulation of cognitive reserve inducing brain plasticity and structural 
changes in both healthy subjects and patients with neurodegenerative conditions16. These proxies of cognitive 
reserve seem to be crucial for processes related to the brain maintenance, leading to protection of brain integrity 
in aging and disease, and resulting in a higher brain reserve16. Several neuroimaging studies17–20 focused on brain 
reserve16, which is now recognized as one of the most powerful protective mechanism for cognitive decline and 
dementia15. These studies have suggested that high levels of reserve allowing cope with brain neurodegeneration, 
delaying the onset of clinical manifestation and leading to a higher tolerance to underlying pathology17–20.
We hypothesized possible modulatory effects of BMI on brain neurodegeneration and functional connectivity, 
and specifically a detrimental effect of high BMI and obesity on brain reserve, leading to major vulnerability to 
neuropathology. We thus studied a large group of patients with probable Alzheimer’s Dementia (AD), who under-
went 18F-FDG-PET, in order to assess the effects of BMI levels on brain metabolism and connectivity, crucial 
measures of synaptic function and activity, while also considering the role of gender.
Results
Group analyses. We first estimated AD-related hypometabolism by comparing AD patients with a large 
group of healthy controls. In the patients, the comparison showed the typical AD-like pattern (p < 0.05 FWE 
corrected for multiple comparison, k:100 voxels), with an extended and significant hypometabolism in the pari-
etal-temporal cortex, and in the posterior cingulate cortex and precuneus (Fig. 1a). We then tested for differences 
in brain hypometabolism in AD patients with low BMI vs. high BMI, separately for female and male subgroups 
(p < 0.05 FWE corrected for multiple comparison, cluster extent (k) threshold at 100 voxels). The results showed 
a less severe and extended pattern of hypometabolism in the high BMI compared to the low BMI female subgroup 
and no differences between the male BMI subgroups (voxel-level p < 0.05 FDR corrected for multiple compari-
son, k = 100; cluster-level p < 0.05 FWE-corrected) (Fig. 1b,c). A multiple regression model confirmed the BMI x 
Gender interaction effect on brain metabolism in AD-signature brain regions (F = 6.185, p = 0.014; N = 206). 
There were no significant interaction effects between BMI and either age, education or APOE status on brain 
metabolism, neither in the whole AD group nor in gender subgroups.
Metabolic correlation analysis. The correlation analysis between BMI levels and brain metabolism, in 
regions typically affected by AD and representing the metabolic hallmarks of the disease, revealed no correlations 
in the whole AD group (R = 0.053, p = 0.45; partial R = 0.045, p = 0.52; N = 206). Considering gender, there was 
again no significant correlation in males (R = −0.010, p = 0.92; partial R = −0.055, p = 0.58; N = 112), whereas in 
females we found a significant positive correlation between BMI levels and glucose metabolism in the AD-typical 
affected regions (R = 0.269, p = 0.009; N = 94), also after controlling for age, disease duration, years of education 
and cognitive impairment, as measured by Mini-Mental State Examination (MMSE)(partial R = 0.224, p = 0.034; 
N = 94) (Fig. 2).
Metabolic connectivity analysis. We tested whether there were significant modulation effects by BMI 
levels on connectivity strength in the main brain resting-state networks, i.e. the anterior and posterior Default 
Mode Networks (aDMN, pDMN), the Executive Control Network, the Attentional and the Salience Networks, the 
Limbic and Reward Networks. In the whole AD group, BMI had no effect on metabolic connectivity in any of the 
examined resting-state networks. When considering gender, however, females with higher BMI scores showed a 
lower connectivity between regions of the aDMN (specifically the anterior and right middle cingulum, right supe-
rior and middle frontal cortex, right olfactory cortex, left ventral striatum and right caudate nucleus; voxel-level 
p < 0.05 FDR-corrected, k = 100; cluster-level p < 0.05 FWE corrected; N = 94) and in the Salience network (spe-
cifically in the anterior and middle cingulum bilaterally, superior medial frontal gyrus, medial orbitofrontal gyrus, 
right insula, right rolandic operculum, right temporal pole, right superior temporal gyrus, right middle and infe-
rior frontal gyrus; voxel-level p < 0.05 FDR-corrected, k = 100; cluster-level p < 0.05 FWE corrected; N = 94) 
(Fig. 3). No significant effect of BMI on brain networks’ connectivity was found in the male subgroup.
There were no significant interaction effects between BMI and either age, education or APOE status on brain 
metabolic connectivity in any resting-state network, in neither the whole AD group nor in the gender subgroups.
Discussion
This is the first study exploring the effect of BMI on brain metabolism and connectivity, as major parameters of 
neural functionality, in a large sample of AD patients and also considering gender. Our findings reveal a negative 
effect of high BMI on brain metabolism in female AD patients. At comparable clinical severity, AD females with 
higher BMI levels showed less severe hypometabolism in AD-typical brain regions and reduced metabolic con-
nectivity in fundamental resting-state functional networks. This suggests that, at comparable dementia severity, 
females with high BMI can withstand a lower degree of brain dysfunction and show greater vulnerability of brain 
networks, all the above reflecting reduced brain reserve mechanisms. Thus, we suggest that high BMI may exert a 
detrimental effect in the brain of female AD patients.
Our results suggest that a high BMI influences neurodegeneration and clinical manifestations in AD. 
Although AD neurodegeneration causes a reduction of brain metabolism in all patients, females with high BMI 
showed less brain hypometabolism than female with low BMI that was enough to cause comparable cognitive 
deficits and dementia (see Fig. 1). This result was also confirmed by the presence of a significant positive corre-
lation between BMI and brain metabolism, controlling for age, disease duration, years of education and level of 
cognitive impairment. It may thus be conceived that, at a comparable degree of clinical severity, high BMI makes 
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female AD patients to tolerate a lower load of neuropathological changes (Fig. 4). These findings are in agreement 
with the brain reserve theory16 originally described to explain the discrepancy between the quantity of neuro-
pathology and the clinical expression in AD18. In several studies, life experiences have been reported as involved 
in the modulation of brain plasticity and structural changes in both healthy subjects and neurodegenerative con-
ditions16. In spite of the absence of thorough information about occupation and other socioeconomic variables in 
our database, data on education were available, and these were controlled for. Of note, a previous study reported 
no significant effects of socioeconomic status on the association between education and risk for Alzheimer’s 
Disease21, also suggesting that education represents a much more important factor than socioeconomic status in 
Alzheimer’s disease.
Here, we show that a high BMI can be detrimental, causing less tolerance to underlying AD pathology, whereas 
a low BMI may contribute to neuroprotective mechanisms in dementia, particularly in females. Considering that 
Figure 1. Brain hypometabolism AD patterns. (a) SPM-group analysis showing the typical AD brain 
hypometabolism pattern in the whole AD group. The analysis result is showed at p < 0.05 FWE corrected for 
multiple comparisons. (b) SPM-group analysis showing the typical AD brain hypometabolism pattern across 
low BMI vs. high BMI subgroups, separately for males and females (p < 0.05 FWE corrected for multiple 
comparison, k:100 voxels). (c) Results of the two-sample t-test comparisons between low BMI vs. high BMI 
gender subgroups. Significantly lower hypometabolism is present in precuneus/posterior cingulate cortex and 
parieto-temporal regions in females with high BMI as compared to females with low BMI (voxel-level p < 0.05 
FDR corrected for multiple comparison, k = 100 voxels; cluster-level p < 0.05 FWE-corrected). No significant 
difference is revealed when comparing males with low vs. high BMI. The left side of the brain is shown on the 
left in the figure. Results are displayed on a 3D brain template using Brainnet toolbox48.
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the underlying AD pathology affects all the patients, it might be conceived that a high BMI leads to worse cog-
nitive outcomes in the presence of AD neurodegeneration than low BMI. This interpretation is also supported 
by many studies which described a negative correlation between BMI levels and cognitive functioning during 
healthy lifetime3,6,12, and by the limited MRI structural evidence in healthy aging22–25, MCI and AD patients26,27 
reporting an association of high BMI with reduced volumes of several brain regions, such as frontal, temporal, 
and occipital lobes, and brainstem.
The second main result of the present research study concerns the effects of BMI on brain metabolic connec-
tivity, which is based on the assumption that regions whose metabolism is correlated are functionally intercon-
nected28. Notably, only in the female AD group, high BMI, in comparison to low BMI, was associated with reduced 
metabolic connectivity of aDMN and Salience Network, in limbic and frontal regions (i.e. insula, anterior cingu-
lum, medial frontal regions, orbitofrontal cortex and ventral striatum), crucially involved in reward processing and 
executive control (Fig. 3). In agreement with this result, two previous functional-MRI studies, exploring the func-
tional brain connectivity in a group of obese adults, found decreased connectivity in the right anterior cingulate 
cortex and left insula29,30. These regions are crucially implicated in the rewarding effects of food, and the disruption 
of the reward-saliency circuit is indeed thought to be a key mechanism in obesity, increasing the reinforcing value 
of food and weakening control circuits29. Thus, we suggest that the above reported dysfunction in brain regions, 
which are related to reward mechanisms and executive control in obesity31, also reflects the detrimental effect of 
obesity on brain functioning in dementia. Of note, in a previous study, we found these specific brain regions to 
be crucial for brain reserve in both female AD patients and female healthy elderlies18. Specifically, the two female 
groups showed significant correlations between levels of brain reserve and brain metabolism in anterior-limbic and 
executive brain regions18. These results suggest that, in females, these anterior brain structures are mainly involved 
in brain compensatory processes to cope with both aging and dementia18. Considering all the above evidence, we 
suggest that high BMI could exert a detrimental effect on brain reserve also contributing to the vulnerability of 
neural systems selectively involved in protective mechanisms in both healthy aged and AD females18.
The significant effect of BMI on both brain metabolism and metabolic connectivity was not found in male 
patients. Despite similar obesity rates between sexes32, differences exist in the adverse effects of obesity on the 
brain, which seem to be exaggerated in women (see for review33). Although only few studies have explored gender 
differences in the relation between obesity and dementia risk, they suggest with some coherence that negative 
effects of obesity on cognitive functioning and AD risk are stronger in women than in men33. In particular, obese 
women show an increased disruption of blood-brain barrier34, temporal lobe atrophy35 and myelin degenera-
tion36, resulting also in an increased rate of AD risk.
While there is some evidence for a gender effect on the obesity-related AD risk, the nature of this relationship 
is not completely understood. ApoeE4 and inflammation seem to be particularly involved, as they are associated 
with AD risk and obesity, showing stronger negative effects in females than in males (see for review33). Other fac-
tors influencing sex differences in obesity and dementia, such as insulin resistance, need to be considered. There is 
recent evidence for an association between the metabolic marker insulin resistance and AD (see for review37). The 
disturbances in glucose metabolism and insulin resistance were shown to be associated with neurodegeneration, 
accelerated cognitive decline and increased dementia risk37. Since insulin resistance is directly correlated with 
BMI, it may be the case that females with higher BMI are the most insulin-resistant, with important detrimental 
effects on the brain reserve in dementia. Unfortunately, the retrospective design of the present study did not allow 
us to include such a biomarker in the analysis.
Figure 2. Correlation between BMI and metabolism in key AD regions. The graph displays the correlations 
between BMI (x axis) and SPM contrast values of 18F-FDG-PET glucose metabolism (y axis) in regions typically 
affected by AD, separately for females and males AD patients. A significant positive correlation is found for 
female AD patients (pink line; R = 0.269, p = 0.009; partial R = 0.224, p = 0.034); no correlation is reported for 
male AD patients (blue line; R = −0.010, p = 0.92; partial R = −0.055, p = 0.58; N = 112). Pink and blue shaded 
areas represent confidence intervals for regression lines’ slopes, in females and males AD patients, respectively.
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Our study provides a first neurobiological evidence of the effect of high BMI levels on brain dysfunction in 
AD dementia, with female/male differences. Other biological and social factors in interaction with BMI may lead 
to gender-specific reorganization of brain functional networks, also limiting the neuroprotective mechanisms in 
dementia, which are in need to be further explored.
Methods
Subjects. We included 206 subjects with a clinical diagnosis of probable AD according to standard diag-
nostic criteria38 (females/males: 94/112; age: 72.27 ± 7.78 years; years of education 12.95 ± 4.38; disease dura-
tion: 3.72 ± 2.38 years; MMSE: 21.24 ± 4.03). They were recruited from two databases: 88 from the San Raffaele 
Hospital (Milan, Italy) and 118 from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (http://
adni.loni.usc.edu/). The ADNI was launched in 2003 as a public-private partnership, led by Principal Investigator 
Figure 3. Significant modulatory effects by BMI level on brain metabolic connectivity of aDMN (a) and 
Salience Network (b), in female AD patients. Left panel: Panel showing, in blue, the brain regions belonging to 
the aDMN (a) and Salience Network (b). Networks’ seeds (i.e. ACC for aDMN and aINS for Salience Network) 
are depicted in black. The left side of the brain is shown on the left in the figure. Middle panel: Connectograms 
show brain regions belonging to each network. The central white dots denote networks’ seeds, i.e. ACC for 
aDMN and aINS for Salience Network. Networks’ regions whose connectivity is significantly modulated by 
BMI (i.e. interaction regions), are depicted in red (voxel-level p < 0.05 FDR-corrected, k = 100; cluster-level 
p < 0.05 FWE corrected). A significant modulatory effect by BMI level on metabolic connectivity is present for 
limbic and frontal regions related to reward processing and executive control. Right panel: the graph shows the 
BMI effects on metabolic connectivity. SPM contrast values in the network’s seeds (ACC for aDMN, aINS for 
Salience Network) on the x axis; SPM contrast values in the relevant fronto-limbic regions (interaction regions) 
on the y axis. The slope beta, representing the strength of metabolic connectivity between the network’s seed and 
the interaction regions, changes at different BMI levels. An increase of BMI corresponds to a reduction of the 
connectivity strength in both aDMN and Salience Network. Results are displayed on a 3D brain template using 
Brainnet toolbox48. Abbreviations: aINS, anterior insula; ACC, anterior cingulate cortex; CaN, caudate nucleus; 
Ins, insula; MCC, middle cingulate cortex; HG, Heschl’s gyrus; IFGOpp, inferior frontal gyrus, pars opercularis; 
IFGOrp, inferior frontal gyrus, pars orbitalis; IFGTrp, inferior frontal gyrus, pars triangularis; MedOrG, medial 
orbitofrontal gyrus; MedSFG, medial superior frontal gyrus; MFG, middle frontal gyrus; MOrG, middle 
orbitofrontal gyrus; OlG, olfactory gyrus; Pu, putamen; RG, gyrus rectus; RO, Rolandic operculum; SFG, 
superior frontal gyrus; SMA, supplementary motor area; SOrG, superior orbitofrontal gyrus; STG, superior 
temporal gyrus; STPo, superior temporal pole; VST, ventral striatum.
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Michael W. Weiner, MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging 
(MRI), PET, other biological markers, and clinical and neuropsychological assessment can be combined to meas-
ure the progression of mild cognitive impairment and early AD.
The AD diagnosis was also supported by the presence of the AD-like brain hypometabolism pattern, as 
assessed in single subjects with an optimized and validated 18F-FDG-PET SPM procedure39. All patients met 
diagnosis for probable AD as defined by National Institute on Aging-Alzheimer’s Association and described in 
McKhann et al.38. This implies absence of stroke and major psychiatric disorders (i.e. depression), as stated in 
the ADNI exclusionary criteria. Patients included in this study did not suffer from diabetes, with the exception 
of six male subjects. We also check the information about glycaemia at the time of PET scan, which was less than 
160 mg/dl in all patients, including those six with diabetes (as recommended by the international guidelines)40.
Demographic characteristics are reported in Table 1 for the whole AD group and gender subgroups that 
were compared by means of two-sample independent t-tests. BMI levels were significantly higher in the male 
group as compared to the female group (t = 3.742, p < 0.001), at consistently with the higher prevalence of obe-
sity and overweight reported in males by epidemiological studies in US and Europe (e.g. Behavioral Risk Factor 
Surveillance study (US); Health Survey for England (UK); Osservasalute (Italy)). However, BMI followed a nor-
mal distribution in both females and males groups, with kurtosis and skewness far below 1.96 in each group 
(females: Kurtosis = 1.150(SE = 0.493); Skewness = 0.859(SE = 0.249)); males: Kurtosis = 0.668(SE = 0.453); 
Skewness = 0.774(SE = 0.228)).
Subjects provided written informed consent, following detailed explanation of each experimental procedure. 
The study was performed in compliance with the Declaration of Helsinki and it was approved by San Raffaele 
Hospital Ethical Committee.
18F-FDG-PET data acquisition and preprocessing. For the Nuclear Medicine Unit database of San 
Raffaele Hospital, the PET scan acquisition was performed according to the European Association of Nuclear 
Medicine guidelines40, while for the ADNI database the acquisition procedure is described in the “ADNI PET 
technical procedures manual, version 9.5” (http://adni.loni.usc.edu/wp-content/uploads/2010/09/PET-Tech_
Procedures_Manual_v9.5.pdf). We created a single averaged 15-minute frame for each image starting at 30 or, 
Figure 4. Pictorial representation of BMI effects on brain hypometabolism, hypothesizing a trajectory 
of cognitive decline and brain hypometabolism across females with low BMI and high BMI. Brain 
hypometabolism is represented on the x axis, cognitive status is depicted on the y axis. The dotted red line 
denotes cognitive status of AD patients with overt dementia, as in the present study. At this time point, severity 
of hypometabolism is significantly lower in high BMI as compared to low BMI AD females (p < 0.05 FDR-
corrected, k = 100 voxels), in spite of comparable cognitive status, as measured by MMSE. This suggests that, in 
females with high BMI, a lesser amount of neurodegeneration is enough to cause dementia symptoms. Results 






(N = 112) P Value
Age (years) 72.27 ± 7.78 70.96 ± 7.93 73.36 ± 7.51 0.03a
Disease Duration (years) 3.72 ± 2.38 3.69 ± 2.45 3.74 ± 2.32 0.87
MMSE 21.24 ± 4.03 20.77 ± 4.51 21.64 ± 3.56 0.12
Education(years) 12.95 ± 4.38 12.16 ± 4.02 13.61 ± 4.57 0.02a
BMI (kg/m2) 24.99 ± 4.51 23.69 ± 4.44 26.08 ± 4.30 0.001a
Table 1. Demographic characteristics (mean ± standard deviation) for whole AD group and gender subgroups, 
and significance of t-test for gender comparisons. Abbreviations: MMSE, mini-mental state examination; BMI, 
body mass index. aSignificant difference at the two-sample t-test comparing males and females.
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in the majority of cases, at 45 minutes after radio-ligand injection. In this way, the uptake time for ADNI images 
was consistent with that of San Raffaele images. Intensity normalization was achieved by dividing each image 
by its global mean, in order to reduce inter-subject and inter-scanner variability41. Single-subject images were 
processed according to an optimized and validated SPM procedure39,42, to obtain individual hypometabolism 
SPM-t-map by means of a two-sample t-test, with the patient’s image being tested against a large database of 112 
normal controls, (p < 0.05 with Family Wise Error (FWE) correction for multiple comparisons; minimum cluster 
extent set at k = 100 voxels). The resulting single-subject hypometabolism pattern was used as support for the 
diagnosis.
Statistical analyses. Group analyses. Patterns of relative hypometabolism were then tested in each gender 
subgroup, split according to BMI (cut-off = 25; i.e. Low BMI (BMI <25); High BMI (BMI >25)). Demographics 
characteristics for each group are reported in Table 2. Significant differences in relative hypometabolism across 
BMI subgroups were assessed separately for females and males, by means of a two-sample t-test. Results were 
considered significant at p < 0.05 FDR-corrected at the voxel level. Only clusters with a minimum extent of 100 
voxels and remaining significant at p < 0.05 FWE-corrected at cluster level were considered.
We also explored the interaction effects of BMI and gender, along with age, education and APOE status 
on brain metabolism by means of multivariable regression models. Significance level was set at α = 0.05, with 
two-tailed significance tests.
Metabolic correlation analyses. We performed separate correlation analyses for the whole AD group and the 
gender subgroups. As ROI, we used the mask obtained from the group-level 18F-FDG-PET hypometabolism SPM 
map, thresholded at a highly conservative statistical significance (p < 0.05 FWE-corrected for multiple compari-
sons; k = 100 voxels), as described above. Next, the mean 18F-FDG uptake value from the ROI was computed for 
each patient and linearly correlated with BMI scores. Age, disease duration, MMSE and years of education were 
then included as nuisance variables in order to factor out their effects.
Metabolic connectivity analysis. The effect of BMI on the brain metabolic connectivity of the resting-state net-
works was investigated in the whole AD group and likewise separately for females and males. In particular, we 
applied the voxel-wise interregional correlation analysis in SPM, as described by Lee et al.43. The main assumption 
of this method is that brain regions whose glucose metabolism is correlated at rest are functionally associated28. 
The seed regions for each considered resting-state network were defined according to Shirer et al.44 (http://findlab.
stanford.edu/functional_ROIs.html), Seeley et al.45 and Tomasi et al.46. In particular, we considered as seeds the 
anterior cingulate cortex for the aDMN44; the posterior cingulum and precuneus for the posterior DMN44; the left 
and right middle frontal and superior frontal gyri for the Executive Control Network45; the left and right parietal 
cortex for the Attentional Network46 and the anterior insula bilaterally for the Salience Network45; the amygdala 
for the Limbic Network46. Finally, the Ventral Striatum for the Reward Network was delineated following basal 
ganglia boundaries as provided by the AAL and manually-drawn on a high-resolution T1 anatomical template in 
accordance to the guidelines by Tziortzi et al.47.
The mean ROI counts were entered as variables of interest in a General Linear Model in SPM5 testing for 
voxel-wise whole-brain correlations in the whole AD group and also separately for females and males. Age and 
gender were considered as nuisance variables. For each resting-state network, we considered the pattern obtained 
by these correlation analyses as an explicit mask to test the effect of BMI on the metabolic connectivity of each 
resting-state network, for the whole AD group and again separately for females and males. Results were consid-
ered significant at p < 0.05 FDR-corrected at the voxel level. Only clusters with a minimum extent of 100 voxels 
and remaining significant at p < 0.05 FWE-corrected at cluster level were considered.
Lastly, we also explored the interaction effects of BMI with age, education and APOE status on the brain met-
abolic connectivity in each resting-state network by means of multivariable regression models.
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